WebJul 21, 2024 · Novel assets and products arising from the collaboration will be the property of the pharmaceutical company and in the event that the feasibility study is successful, the pharmaceutical company... WebDec 20, 2024 · Q-Sphera™ is the next generation micro-encapsulation and polymer-depot sustained release (SR) drug delivery platform developed by Midatech using a novel and …
Sphera Funds Management Ltd. B - GuruFocus.com
WebApr 11, 2024 · Sphera Funds Management LTD. bought a new position in shares of Dyne Therapeutics in the 4th quarter valued at $83,000. Legal & General Group Plc raised its holdings in shares of Dyne Therapeutics by 59.9% during the 2nd quarter. Legal & General Group Plc now owns 12,757 shares of the company's stock worth $88,000 after buying an … WebMay 4, 2024 · Vividion Therapeutics — which formed to transform drug development by targeting “undruggable” proteins — has attracted an $82 million Series B round. The San Diego company wants to create new medicines in challenging areas, through a platform for tough-to-drug protein targets. These proteins lack pockets that small molecules — long ... does mineplex have deathrun
Catabasis Pharmaceuticals Announces New Company ... - Astria Therapeutics
WebXsphera Biosciences Inc 1,681 followers on LinkedIn. About Xsphera Biosciences envisions a world where failure is no longer the most likely outcome in oncology clinical trials. Our ex vivo ... WebJun 17, 2024 · Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time … WebXsphera’s platform preserves the complete tumor microenvironment from a biopsy of a patient’s tumor. This ex vivo system captures the entirety of the tumor microenvironment (TME), including immune cells, tumor cells, and stroma, and preserves it within multiple microfluidic channels. facebook emo nite